

Review

Not peer-reviewed version

Stress as a Catalyst: Understanding its Role in Bowel Cancer

[Abhinandan Patil](#) * and [Neha Singh](#)

Posted Date: 26 March 2024

doi: 10.20944/preprints202403.1511.v1

Keywords: stress; bowel; tumors; psychology



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review

Stress as a Catalyst: Understanding Its Role in Bowel Cancer

Abhinandan Patil ^{1,*} and Neha Singh ²

¹ D. Y. Patil Education Society, (Deemed to be University), Kolhapur

² Department of Microbiology, Pt. JNM Medical Raipur

* Correspondence: abhisirdyp@gmail.com

Abstract: Stress has been identified as a prominent contributor to the development and advancement of bowel cancer, however its specific involvement is intricate and diverse. This abstract tries to offer a concise summary of the correlation between stress and bowel cancer, consolidating significant discoveries from several research fields. The investigation commences by studying the molecular pathways by which chronic stress impacts the development of colon cancer. Chronic stress causes disruption in the functioning of neuroendocrine, immunological, and inflammatory pathways, leading to the development of a microenvironment within the gastrointestinal system that promotes the growth of tumours. Furthermore, changes in the composition of gut microbiota, variations in epigenetics, and alterations in immune function caused by stress also have a role in increasing the risk and advancing the advancement of cancer. Psychological aspects, including how one perceives stress, the tactics they use to cope with it, and the level of psychosocial support they receive, are crucial in determining a person's susceptibility to bowel cancer and impacting the effectiveness of treatment. Stress management therapies, such as cognitive-behavioral therapy and mindfulness-based stress reduction, have demonstrated potential in enhancing patient well-being and promoting adherence to treatment. Moreover, epidemiological studies and clinical trials offer vital knowledge regarding the correlation between stress and the risk, prognosis, and treatment results of bowel cancer. Although the evidence is inconclusive, it is essential to continue researching the intricate relationship between stress and bowel cancer. This will help us understand the connection better and create specific strategies to reduce its impact on patient outcomes.

Keywords: stress; bowel; tumors; psychology

Introduction:

Stress, a commonly encountered aspect of contemporary existence, has been well acknowledged for its significant influence on human well-being. In addition to its immediate psychological and emotional effects, recent research has revealed the complex relationship between stress and physiological processes, suggesting that it may play a role in the onset and advancement of many diseases. Of all these, bowel cancer is particularly noteworthy due to its growing significance and worry. Our review aims to investigate the intricate correlation between stress and bowel cancer. Our investigation thoroughly examines the complex ways by which stress affects the development, advancement, and outlook of bowel cancer. Our goal is to offer a thorough comprehension of how stress acts as a catalyst in the complex process of bowel cancer development, encompassing biological pathways and psychosocial components [1–3]. Through the integration of findings from several disciplines such as molecular biology, psychology, immunology, and epidemiology, our objective is to elucidate the intricate relationships between stress and bowel cancer. By carefully analysing important subtopics, our goal is to clarify the biological, psychological, and clinical aspects of this interaction, which will open up new perspectives and possible therapeutic treatments. As we progress through the upcoming chapters, we encourage readers to embark on this informative trip, delving into the complex connections between stress and bowel cancer and enhancing our comprehension of this crucial component of human health [4,5].

Biological Mechanisms: The Relationship Between the Stress Response and the Development of Bowel Cancer [6–9]

The correlation between stress and bowel cancer is intricately connected to the complex molecular mechanisms that govern the body's reaction to stimuli. Stress initiates a series of physiological reactions, involving intricate interactions among the neuroendocrine, immunological, and inflammatory pathways, which could potentially contribute to the development and advancement of bowel cancer. The hypothalamic-pituitary-adrenal (HPA) axis is a key part of the body's stress response mechanism. When faced with stress, the hypothalamus releases corticotropin-releasing hormone (CRH), which prompts the pituitary gland to generate adrenocorticotropic hormone (ACTH). ACTH stimulates the adrenal glands to secrete cortisol, which is the main hormone associated with stress. The dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and the sustained rise of cortisol levels have been linked to the promotion of tumour formation and the progression of tumours in the colon and rectum. Furthermore, long-term stress can cause changes in the activity of the sympathetic nervous system (SNS), which can affect the functioning of the gastrointestinal tract, including its movement, permeability, and the health of its lining. Disturbance of the balance in the gut may create an environment that promotes inflammation, which can lead to the development of colon cancer. The alterations in the composition and function of gut microbiota caused by stress also contribute to the disruption of gastrointestinal control, potentially worsening the risk of developing bowel cancer.

Stress not only affects hormonal and neuroendocrine pathways, but also has an impact on immunological responses. This, in turn, affects the tumour microenvironment and influences tumour immunity. Chronic stress can inhibit the body's immune system from effectively detecting and fighting against tumours, while also enabling tumours to evade the immune response. This creates a favourable environment for tumour growth and spread in the intestine.

Gaining a comprehensive understanding of the complex molecular processes through which stress affects the development of bowel cancer is essential for identifying new treatment targets and strategies. Through unravelling the intricate relationship between stress and biological pathways, scientists can pinpoint specific therapies that can help reduce the effects of stress on the development and progression of bowel cancer.

Psychological Factors: How the Perception of Stress and Coping Strategies Influence the Development of Bowel Cancer [9–12]

Psychological factors have a substantial impact on how an individual reacts to stress and can affect the emergence and advancement of bowel cancer. Biological mechanisms involved in the development and spread of tumours can be influenced by stress perception, coping techniques, and psychosocial factors like depression, anxiety, and social support. Perceived stress levels differ among individuals and are impacted by personality qualities, previous experiences, and socio-cultural influences. Persistent stress and ineffective ways of dealing with it, such as avoiding or obsessing over problems, have been linked to disrupted physical reactions, including changes in immune system functioning, inflammation, and hormonal imbalances. These factors can all contribute to an increased chance of developing bowel cancer. Psychological distress, such as depression and anxiety, has been associated with changes in the hypothalamic-pituitary-adrenal (HPA) axis, immunological dysfunction, and disruption of inflammatory pathways. These factors can potentially contribute to the development of cancer in the colon. Furthermore, psychological distress can have an effect on health behaviours, including diet, exercise, and medication adherence, which are recognised to have an impact on the risk and prognosis of bowel cancer.

On the other hand, certain good psychosocial characteristics including social support, resilience, and coping methods that involve problem-solving and emotional control can help protect against the harmful effects of stress on the development of bowel cancer. Robust social networks and efficient coping methods have been linked to enhanced immune function, less inflammation, and superior treatment results in persons diagnosed with colon cancer. Gaining insight into the interaction between psychological variables and colon cancer is crucial for the development of comprehensive

strategies for cancer prevention and treatment. Integrating psychosocial interventions, such as cognitive-behavioral therapy, mindfulness-based stress reduction, and support groups, into comprehensive cancer care can enhance individuals' ability to cope, reduce psychological distress, and improve overall well-being among those who are at risk for or have been diagnosed with bowel cancer. Healthcare practitioners can improve patient care and achieve better results in the treatment of colon cancer by addressing psychological aspects.

The Impact of Stress on the Progression of Bowel Cancer via Inflammation and Immune Dysregulation [13–18]

Chronic stress is known to disrupt the control of inflammatory and immunological responses, which are crucial in the development of bowel cancer. Stress can cause changes in the immune system and inflammatory pathways, leading to the development of a microenvironment in the gastrointestinal tract that promotes the formation and spread of colon cancer.

Chronic low-grade inflammation is a primary way in which stress affects the progression of colon cancer. Stress induces the secretion of pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF- α), which can initiate inflammatory signalling pathways in the intestine. Chronic inflammation can result in harm to tissues, changes in DNA, and abnormal cell growth, all of which contribute to the development of cancer in the colon and rectum.

Furthermore, the changes in immune function caused by stress can weaken the body's capacity to identify and eradicate cancer cells. Research has demonstrated that chronic stress can inhibit immune surveillance systems, hinder the activity of natural killer (NK) cells, and diminish T-cell-mediated cytotoxicity. As a result, cancer cells are able to avoid being detected and destroyed by the immune system. In addition, stress can stimulate the proliferation of immunosuppressive cell populations, such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), which further weaken the body's immune responses to tumours. Moreover, alterations in the composition and functionality of the gut microbiota caused by stress can lead to immune system dysregulation and inflammation in the intestine. Dysbiosis, which refers to changes in the structure and diversity of the microbial population, has been linked to higher intestinal permeability, chronic inflammation, and an increased risk of colon cancer. The changes in the makeup of gut microbiota caused by stress might worsen these effects, leading to the creation of an environment that promotes inflammation and facilitates the development and spread of tumours.

Gaining a comprehensive understanding of the complex relationship between stress, inflammation, and immunological dysregulation in the advancement of bowel cancer is essential in order to create precise and focused treatment therapies. Strategies focused on reducing stress-induced inflammation and enhancing immune function show potential for enhancing outcomes in persons who are at risk for or have been diagnosed with colon cancer. By clarifying these fundamental pathways, researchers can establish new methods for cancer prevention, therapy, and management.

Changes in Gut Microbiota: The Impact of Stress on the Composition of Microbes and the Risk of Bowel Cancer [19–24]

The gut microbiota, an intricate community of bacteria that live in the gastrointestinal tract, has a vital function in preserving intestinal balance and impacting the well-being of the host. Recent findings indicate that long-term stress can disrupt the makeup and operation of the gut microbiota, resulting in an imbalance known as dysbiosis. This imbalance, in turn, may play a role in the formation and advancement of colon cancer. Chronic stress has a significant effect on the gut-brain axis, which is a two-way communication pathway connecting the central nervous system with the gut bacteria. Stress can cause changes in the levels of neurotransmitters, hormone production, and intestinal motility. These changes can upset the balance of microbial communities in the gut, leading to an increase in harmful bacteria and a decrease in helpful bacteria. Dysbiosis, which refers to changes in the variety, makeup, and functioning of microorganisms, has been linked to the development of bowel cancer. Changes in the composition of gut bacteria caused by stress can result

in the production of substances that cause inflammation, such as lipopolysaccharides (LPS) and short-chain fatty acids (SCFAs). These substances can lead to inflammation, oxidative stress, and DNA damage in the lining of the intestines, increasing the risk of developing cancer.

Moreover, the dysregulation of gut microbiota caused by stress might hinder the proper functioning of the intestinal barrier, resulting in higher permeability of the mucosal layer and the movement of microbial substances into the bloodstream. This occurrence, referred to as “leaky gut,” has the potential to initiate widespread inflammation, activate the immune system, and increase the likelihood of developing bowel cancer. On the other hand, changes in the composition and function of the gut microbiota can also impact how susceptible a person is to stress. The microbiota-gut-brain axis facilitates bidirectional communication between the gut bacteria and the central nervous system, influencing stress responses, emotional behaviour, and cognitive performance. The dysregulation of the microbial community in the body can lead to changes in the production of neurotransmitters, inflammation in the nervous system, and the ability of the brain to adapt. These changes may play a role in the development of psychiatric disorders connected to stress, which in turn can worsen the interaction between stress and the microbiota.

Comprehending the two-way connection between stress, changes in gut microbiota, and the likelihood of developing bowel cancer is crucial for creating specific interventions to control the gut microbiota and reduce the risk of cancer caused by stress. Strategies focused on rebalancing the microbial composition, enhancing the integrity of the intestinal barrier, and regulating stress responses show potential for decreasing the incidence of bowel cancer and enhancing outcomes in persons experiencing long-term stress.

Epigenetic Alterations: Stress-Induced Modifications and their Consequences in Colorectal Cancer [25–29]

Epigenetic alterations, including as DNA methylation, histone modifications, and regulation by non-coding RNA, are essential for controlling gene expression patterns and cellular function. Recent research indicates that long-term stress can cause extensive alterations in the epigenome, which can impact the growth and advancement of colorectal cancer.

Chronic stress has been linked to changes in DNA methylation patterns, namely in genes related to tumour suppression, DNA repair, and immunological modulation. The abnormal increase in methylation of promoters of tumour suppressor genes and the decrease in methylation of oncogenes can disturb the normal functioning of cells, leading to the development of cancer in the intestine. Changes in DNA methylation caused by stress can result in abnormal gene expression patterns, which can contribute to the development, expansion, and spread of tumours.

In addition, long-term stress can impact histone changes, including acetylation, methylation, and phosphorylation, which control the structure of chromatin and the transcription of genes. Disruption of the patterns of histone modifications can change how easily DNA can be accessed by transcription factors and RNA polymerase, which in turn affects the gene expression programmes involved in the development of bowel cancer. Stress-induced alterations in histone structure may enhance the growth, spread, and migration of cancer cells by influencing critical signalling pathways associated with the development of tumours. Non-coding RNAs, such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), are now recognised as significant regulators of gene expression in bowel cancer. Chronic stress can alter the expression of these non-coding RNAs, causing disruption of downstream target genes that are involved in the progression of cancer. Changes in miRNA expression profiles caused by stress can impact cellular processes like proliferation, apoptosis, and metastasis, which can contribute to the development and progression of bowel cancer. Gaining a comprehensive understanding of the epigenetic mechanisms that contribute to the impact of long-term stress on the development of bowel cancer is essential in order to discover new targets for therapy and treatments. Epigenetic therapeutics and lifestyle interventions are potential strategies for rectifying stress-induced epigenetic alterations. These strategies show promise in reducing the risk of bowel cancer caused by stress and improving the outcomes for patients. Through the

clarification of the intricate relationship between stress and epigenetic regulation, scientists can provide the foundation for individualised strategies in the prevention and treatment of cancer.

Clinical Evidence: Epidemiological Studies and Clinical Trials Examining the Association Between Stress and Bowel Cancer [30–34]

Epidemiological studies and clinical trials offer vital insights into the correlation between stress and the risk, prognosis, and treatment results of colon cancer. Through the examination of extensive groups of individuals and the implementation of well regulated therapies, researchers can clarify the influence of stress on many facets of bowel cancer, encompassing its occurrence and the rates at which individuals survive the disease. Studies in the field of epidemiology have shown inconclusive results about the correlation between stress and the risk of developing bowel cancer. While certain research indicate a favourable correlation between long-term stress and a heightened likelihood of developing bowel cancer, other studies have not been able to show a substantial connection. Differences in the design of research, methods used to assess stress, and factors that may affect the results can all contribute to variations in findings observed in different studies.

Moreover, clinical trials examining the impact of stress management therapies on colon cancer outcomes have yielded useful knowledge regarding the possible therapeutic advantages of stress reduction measures. The effectiveness of interventions such as cognitive-behavioral therapy, mindfulness-based stress reduction, and relaxation techniques has been assessed in colon cancer patients to determine their impact on improving quality of life, lowering psychological distress, and increasing treatment adherence. Furthermore, recent studies indicate that stress can impact the effectiveness of cancer therapies and the overall survival rates of patients. Chronic stress has been linked to less effective treatment outcomes, heightened treatment-related adverse effects, and reduced overall survival rates in persons diagnosed with colon cancer. Gaining insight into the influence of stress on treatment results is essential for enhancing patient care and formulating tailored treatment strategies. Through the synthesis of evidence from epidemiological studies and clinical trials, researchers may develop a thorough understanding of the association between stress and bowel cancer, as well as its implications for patient management. Implementing strategies that target stress reduction, enhance coping mechanisms, and incorporate psychosocial support into the care of patients at risk for or diagnosed with colon cancer may have the potential to improve outcomes. By persistently doing research, we can gain a deeper understanding of how stress contributes to the development of bowel cancer and create specific strategies to reduce its negative effects on patient outcomes.

Conclusion:

Overall, studying stress as a catalyst in the context of bowel cancer offers useful insights into the complex relationship between psychological, biological, and environmental components in the development of cancer. During this inquiry, we have explored various facets of this association, including biological causes, psychological factors, inflammation, changes in gut microbiota, epigenetic modifications, and clinical data. Our study emphasises the intricate connection between stress and bowel cancer, specifically focusing on the intricate interactions between stress and several biochemical processes involved in the development, advancement, and response to therapy of tumours. Chronic stress has significant impacts on the neuroendocrine, immunological, and inflammatory systems, leading to the development of a microenvironment in the gastrointestinal tract that promotes the growth of tumours. Additionally, psychological factors, including the perception of stress, coping mechanisms, and psychosocial support, have a substantial impact on an individual's susceptibility to bowel cancer and can influence the effectiveness of treatment. The association between stress and cancer is better understood via the study of changes in the composition of gut bacteria, adjustments in gene activity caused by stress, and clinical data. These findings offer useful information for developing possible treatments for cancer related to stress. In order to better understand the connection between stress and bowel cancer, it is crucial to do further study. This research will help uncover the mechanisms that link stress to the development of cancer

and allow for the development of specific interventions that can reduce the influence of stress on cancer risk and prognosis. To improve the outcomes and quality of life for those at risk for or diagnosed with bowel cancer, it is important to incorporate psychosocial support into comprehensive cancer care, optimise stress management measures, and promote resilience.

References

1. Afzal M, Mazhar SF, Sana S, Naeem M, Rasool MH, Saqalein M, et al. Neurological and cognitive significance of probiotics: a holy grail deciding individual personality. *Future Microbiol.* 2020;15:1059–1074. doi: 10.2217/fmb-2019-0143.
2. Markowiak P, Slizewska K. Effects of probiotics, prebiotics, and synbiotics on human health. *Nutrients.* 2017;9. doi: 10.3390/nu9091021.
3. Kazemian N, Mahmoudi M, Halperin F, Wu JC, Pakpour S. Gut microbiota and cardiovascular disease: opportunities and challenges. *Microbiome.* 2020;8(1):36. doi: 10.1186/s40168-020-00821-0.
4. Hills RD Jr, Pontefract BA, Mishcon HR, Black CA, Sutton SC, Theberge CR. Gut microbiome: profound implications for diet and disease. *Nutrients.* 2019;11. doi: 10.3390/nu11071613.
5. Panebianco C, Andriulli A, Paziienza V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. *Microbiome.* 2018;6(1):92. doi: 10.1186/s40168-018-0483-7.
6. Khan AA, Shrivastava A, Khurshid M. Normal to cancer microbiome transformation and its implication in cancer diagnosis. *Biochem. Biophys. Res. Commun.* 2012;1826(2):331–337. doi: 10.1016/j.bbcan.2012.05.005.
7. Khan AA, Nema V, Khan Z. Current status of probiotics for prevention and management of gastrointestinal cancers. *Expert Opin. Biol. Ther.* 2020;20(1):1–9. doi: 10.1080/14712598.2021.1828858.
8. Khan AA, Khurshid M, Khan S, Alshamsan A. Gut microbiota and probiotics: current status and their role in cancer therapeutics. *Drug Dev. Res.* 2013;74(6):365–375. doi: 10.1002/ddr.21087.
9. Sedighi M, Zahedi Bialvaei A, Hamblin MR, Ohadi E, Asadi A, Halajzadeh M, et al. Therapeutic bacteria to combat cancer: current advances, challenges, and opportunities. *Cancer Med.* 2019;8(6):3167–3181. doi: 10.1002/cam4.2148.
10. Zur HH. The search for infectious causes of human cancers: where and why. *Virology.* 2009;392(1):1–10. doi: 10.1016/j.virol.2009.06.001.
11. Ishaq S, Numm L. *Helicobacter pylori* and gastric cancer: a state of the art review. *Gastroenterol Hepatol Bed Bench.* 2015;8(Suppl 1):S6–S14.
12. Khan AA, Abuderman AA, Ashraf MT, Khan Z. Protein-protein interactions of HPV-Chlamydia trachomatis-human and their potential in cervical cancer. *Future Microbiol.* 2020;15:509–520. doi: 10.2217/fmb-2019-0242.
13. Khan AA, Khan Z, Malik A, Kalam MA, Cash P, Ashraf MT, et al. Colorectal cancer-inflammatory bowel disease nexus and felony of *Escherichia coli*. *Life Sci.* 2017;180:60–67. doi: 10.1016/j.lfs.2017.05.016.
14. Khan AA, Khan Z, Malik A, Shrivastava A, Jain SK, Alshamsan A. Computational prediction of *Escherichia coli* proteins targeting the host cell nucleus, with special reference to their role in colon cancer etiology. *Cancer Lett.* 2015;364(1):25–32. doi: 10.1016/j.canlet.2015.04.024.
15. Khan AA. In silico prediction of *Escherichia coli* proteins targeting the host cell nucleus, with special reference to their role in colon cancer etiology. *J. Comput. Biol.* 2014;21(6):466–475. doi: 10.1089/cmb.2014.0001.
16. Khan AA, Cash PE. *E. coli* and colon cancer: is *mutY* a culprit? *Cancer Lett.* 2013;341(2):127–131. doi: 10.1016/j.canlet.2013.08.003.
17. Tewari M, Mishra RR, Shukla HS. *Salmonella typhi* and gallbladder cancer: report from an endemic region. *HBPD INT.* 2010;9(5):524–530.
18. Sheflin AM, Whitney AK, Weir TL. Cancer-promoting effects of microbial dysbiosis. *Curr. Oncol. Rep.* 2014;16(10):406. doi: 10.1007/s11912-014-0406-0.
19. Jenkins SV, Robeson II MS, Griffin RJ, Quick CM, Siegel ER, Cannon MJ, et al. Gastrointestinal tract dysbiosis enhances distal tumor progression through suppression of leukocyte trafficking. *Cancer Res.* 2019;79(23):5999–6009. doi: 10.1158/0008-5472.CAN-18-4108.
20. Gao Z, Guo B, Gao R, Zhu Q, Qin H. Microbiota dysbiosis is associated with colorectal cancer. *Front Microbiol.* 2015;6:20. doi: 10.3389/fmicb.2015.00020.
21. Xuan C, Shamonki JM, Chung A, Dinome ML, Chung M, Sieling PA, et al. Microbial dysbiosis is associated with human breast cancer. *PLoS ONE.* 2014;9(1):e83744. doi: 10.1371/journal.pone.0083744.
22. Malla MA, Dubey A, Kumar A, Patil A, Ahmad S, Kothari R, Yadav S. Optimization and elucidation of organophosphorus and pyrethroid degradation pathways by a novel bacterial consortium C3 using RSM and GC-MS-based metabolomics. *J Taiwan Inst Chem Eng.* 2021;144:104744.
23. Munot N, Kandekar U, Rikame C, Patil A, Sengupta P, Urooj S, Bilal A. Improved Mucoadhesion, Permeation and In Vitro Anticancer Potential of Synthesized Thiolated Acacia and Karaya Gum Combination: A Systematic Study. *Molecules.* 2022;27(20):6829.
24. Munot N, Kandekar U, Giram PS, Khot K, Patil A, Cavalu S. A Comparative Study of Quercetin-Loaded Nanocochleates and Liposomes: Formulation, Characterization, Assessment of Degradation and In Vitro Anticancer Potential. *Pharmaceutics.* 2022;14(8):1601.

25. Manikyam HK, Tripathi P, Patil SB, Lamichhane J, Chaitanya M, et al. Extraction, purification, and quantification of hesperidin from the immature *Citrus grandis/maxima* fruit Nepal cultivar. *Asian J Nat Prod Biochem.* 2020;20(1).
26. Patil A, Munot N, Patwekar M, Patwekar F, Ahmad I, Alraey Y, Alghamdi S, et al. Encapsulation of lactic acid bacteria by lyophilization with its effects on viability and adhesion properties. *Evid. Based Complementary Altern. Med.* 2022;2022.
27. Nalawade AS, Gurav RV, Patil AR, Patwekar M, Patwekar F. A comprehensive review on morphological, genetic and phytochemical diversity, breeding and bioprospecting studies of genus *Chlorophytum* Ker Gawl. from India. *Trends Phytochem. Res.* 2022;6(1):19-45.
28. Patil KG, Balkundhi S, Joshi H, Ghewade G. Mehsana buffalo milk as prebiotics for growth of *Lactobacillus*. *Int J Pharm Pharm Res.* 2011;1(1):114-117.
29. Das N, Ray N, Patil AR, Saini SS, Waghmode B, Ghosh C, Patil SB, et al. Inhibitory effect of selected Indian honey on colon cancer cell growth by inducing apoptosis and targeting the β -catenin/Wnt pathway. *Food & Funct.* 2022;13(15):8283-8303.
30. Patil MJ, Patil AG, Patil DA, Patil SP, Patil AR. Screening and characterization of antifungal substances from probiotics against *Candida* species. *Int J Pharm Pharm Res.* 2013;4(2):149-156.
31. Munot NM, Shinde YD, Shah P, Patil A, Patil SB, Bhinge SD. Formulation and Evaluation of Chitosan-PLGA Biocomposite Scaffolds Incorporated with Quercetin Liposomes Made by QbD Approach for Improved Healing of Oral Lesions. *AAPS PharmSciTech.* 2023;24(6):147.
32. Patil A. Psychology in the Age of Technology Dependence and the Mobile Dilemma. *Preprints.org.* 2023;2023070101. <https://doi.org/10.20944/preprints202307.0101.v1>
33. Patil A, Kotekar D, Chavan G. Knowing the Mechanisms: How Probiotics Affect the Development and Progression of Cancer. *Preprints.org.* 2023;2023070243. <https://doi.org/10.20944/preprints202307.0243.v1>
34. Pawar V, Patil A, Tamboli F, Gaikwad D, Mali D, Shinde A. Harnessing the Power of AI in Pharmacokinetics and Pharmacodynamics: A Comprehensive Review. *Int. J. Pharm. Qual. Assur.* 2021;14(2):426-439.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.